Ģ����ý

• Hemodiafiltration (HDF) research reinforces Ģ����ýĢ����ý�s continued leadership in advancing evidence-based dialysis care and treatment personalization
• New research focuses on applying real-world evidence, patient-centered outcomes and artificial intelligence across dialysis modalities and continuity of kidney care
• A preview of kinexus, a unified digital platform intended to support home dialysis programs by connecting therapy management and care workflows

��

Bad Homburg (May 27, 2026)��Ģ����ý� Ģ����ý (FME), the worldĢ����ý�s leading provider of products and services for individuals with kidney diseases, presents new research highlighting ongoing innovation at the European Renal Association (ERA) Congress 2026, June 3-6 in Glasgow, Scotland, and virtually. The Company highlights advancements including new hemodiafiltration research that reaffirm its leadership in evidence��based and personalized dialysis care, real-world evidence to strengthen patient��centered outcomes across dialysis modalities, and the application of artificial intelligence (AI) to improve patient outcomes.��

Ģ����ý�Ģ����ý is focused on the research that can meaningfully advance the standard of care for people living with kidney disease,Ģ����ý� said Charles��Hugh-Jones, Global Chief Medical Officer at Ģ����ý. Ģ����ý�At ERA Congress 2026, we continue demonstrating our CompanyĢ����ý�s leadership in evidence-based hemodiafiltration research and present abstracts covering the use of real-world evidence, patient-centered outcomes and artificial intelligence that are designed to help clinicians make better informed decisions and support patients across multiple care settings.Ģ����ý�

FMEĢ����ý�s Global Medical Office and Renal Research Institute (RRI) teams present multiple abstracts across a range of critical topics in nephrology, demonstrating how data, artificial intelligence, and patient-centered outcomes are shaping the future of kidney care.

Key presentations include:

• Impact of Matching and Weighting Strategy on Patient Retention and 3Ģ����ý�Year Mortality in RealĢ����ý�World Hemodialysis and Hemodiafiltration:��In a real-world analysis, hemodiafiltration was associated with lower three-year mortality risk than hemodialysis, with consistent results across different comparison methods.
• The Association Between PatientĢ����ý�Reported Dialysis Recovery Time and Missed Treatments:��Hemodialysis patients who reported longer recovery times after treatment also had a higher number of missed treatments.
• ClinicsĢ����ý� Utilization of an AI-Based Model Predicting Peritoneal Dialysis Dropouts Is Associated with Lower Hospitalization Rates:��Clinics with higher use of an AI-based dashboard for��identifying peritoneal dialysis patients at risk of dropping out saw lower all-cause hospitalization rates.
• A HighĢ����ý�Precision LargeĢ����ý�Language Model Approach for Abstract Screening in Systematic Reviews:��GPT-5 may help researchers sort through large numbers of research studies by��identifying ones that are most relevant.

In addition to these presentations, FME leaders and researchers will also be available onsite at Booth #C.210 and the Renal Research InstituteĢ����ý�s Booth #C.410 to discuss research insights, clinical collaborations, and innovations in kidney care.��

As part of its broader innovation portfolio highlighted at the Congress, FME previews kinexus, a unified digital platform for home dialysis. Designed as a single, integrated ecosystem, kinexus brings together remote therapy management and operational workflows to help simplify care processes for healthcare teams and support high-quality, personalized care for��patients��dialyzing at home.

To learn more about FMEĢ����ý�s presence at ERA, please click��here.